NCT03127319

A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Affiliated Hospital of Hebei University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the efficacy and safety of patients who receive apatinib plus docetaxel and zoledronic versus docetaxel and zoledronic alone as second line treatment for advanced non-squamous non-small cell lung cancer with bone metastases.

Conditions

• Non-squamous Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	apatinib docetaxel zoledronic	apatinib 500 mg qd p.o.docetaxel 60mg/m² iv q3w;zoledronic 4mg iv\>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
DRUG	docetaxel zoledronic	docetaxel 60mg/m² iv q3w;zoledronic 4mg iv\>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent

Timeline

• Start date: 2017-07-03
• Primary completion: 2019-04-01
• Completion: 2019-12-01
• First posted: 2017-04-25
• Last updated: 2018-01-17

Locations

1 site across 1 country: China